NRAS and neoplasm: The variant allele frequencies (VAFs) of the PIK3CA and NRAS mutations were relatively low (median, 6%; range, 1–38%), compatible with relatively low histopathologic estimated percentage of tumor nuclei (%TN) to overall cellular nuclei (median, 20%; range, 10–70%).